Aim: Previous studies have suggested that quercetin is effective for treating diverse chronic disorders including organ fibrosis and airway and cardiovascular disorders. To access the pharmacological background for its broad efficacy, we examined the ability of quercetin to modulate the inflammatory and fibrotic responses associated with organ injury that commonly underlie the pathogenesis of those disorders. Methods: A cutaneous wound model on rabbit ear was used for in vivo study. Quercetin was topically applied to the wounds, and the number of macrophages and myofibroblasts and the size of the hypertrophic scar formed were estimated. An in vitro study examined the ability of quercetin to inhibit cell-signaling pathways that activate RAW264.7 macrophages and primary dermal fibroblasts and the tyrosine kinase activity of discoidin domain receptor 2. Results: Quercetin reduced the population of macrophages and myofibroblasts and the scar formation in cutaneous wound healing. Quercetin suppressed the signaling pathways activating RAW264.7 macrophages and dermal fibroblasts, which is associated with its inhibition of multiple tyrosine kinases to regulate the pathways. This pharmacological activity of quercetin to simultaneously inhibit the inflammatory and fibrotic responses upon tissue damage by targeting multi-kinases could be the action mechanism to support its broad efficacy for various chronic disorders.

Keywords:
Quercetin, Organ injury, Inflammation, Fibrosis, Pharmacological mechanism
1.
Gormaz JG, Quintremil S, Rodrigo R: Cardiovascular disease: a target for the pharmacological effects of quercetin. Curr Top Med Chem 2015; 15: 1735–1742.
2.
Miles SL, McFarland M, Niles RM: Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease. Nutr Rev 2014; 72: 720–734.
3.
Min YD, Choi CH, Bark H, Son HY, Park HH, Lee S, Park JW, Park EK, Shin HI, Kim SH: Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res 2007; 56: 210–215.
4.
Rogerio AP, Kanashiro A, Fontanari C, da Silva EV, Lucisano-Valim YM, Soares EG, Faccioli LH: Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm Res 2007; 56: 402–408.
5.
Chuang CC, Martinez K, Xie G, Kennedy A, Bumrungpert A, Overman A, Jia W, McIntosh MK: Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 2010; 92: 1511–1521.
6.
Ortega MG, Saragusti AC, Cabrera JL, Chiabrando GA: Quercetin tetraacetyl derivative inhibits LPS-induced nitric oxide synthase (iNOS) expression in J774A.1 cells. Arch Biochem Biophys 2010; 498: 105–110.
7.
Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, Motobayashi Y, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Minakuchi K, Tamaki T: Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci 2009; 109: 257–264.
8.
Zhou J, Fang L, Liao J, Li L, Yao W, Xiong Z, Zhou X: Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo. PLoS One 2017; 12:e0172838.
9.
Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R, Palumbo R: Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res 2014; 159: 185–205.
10.
Refolo MG, D’Alessandro R, Malerba N, Laezza C, Bifulco M, Messa C, Caruso MG, Notarnicola M, Tutino V: Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines. J Cell Physiol 2015; 230: 2973–2980.
11.
Anand David AV, Arulmoli R, Parasuraman S: Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacogn Rev 2016; 10: 84–89.
12.
Zhang M, Swarts SG, Yin L, Liu C, Tian Y, Cao Y, Swarts M, Yang S, Zhang SB, Zhang K, Ju S, Olek DJ Jr, Schwartz L, Keng PC, Howell R, Zhang L, Okunieff P: Antioxidant properties of quercetin. Adv Exp Med Biol 2011; 701: 283–289.
13.
Peet GW, Liu J: IκB kinases α and β show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin. J Biol Chem 1999; 274: 32655–32661.
14.
Houseman BT, Huh JH, Kron SJ, Mrksich M: Peptide chips for the quantitative evaluation of protein kinase activity. Nat Biotechnol 2002; 20: 270–274.
15.
Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM: Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003; 1: 1079–1088.
16.
Navarro-Núñez L, Rivera J, Guerrero JA, Martínez C, Vicente V, Lozano ML: Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR1 and PAR4 in platelets. Br J Pharmacol 2009; 158: 1548–1556.
17.
Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, Bode AM, Lee HJ, Dong Z: Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 2008; 68: 946–955.
18.
Varma SD, Mikuni I, Kinoshita JH: Flavonoids as inhibitors of lens aldose reductase. Science 1975; 188: 1215–1216.
19.
Matsuda H, Morikawa T, Toguchida I, Yoshikawa M: Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull (Tokyo) 2002; 50: 788–795.
20.
Avci CB, Yilmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, Baran Y, Gunduz C: Quercetin-induced apoptosis involves increased hTERT enzyme activity of leukemic cells. Hematology 2011; 16: 303–307.
21.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252–4263.
22.
Elia G, Santoro MG: Regulation of heat shock protein synthesis by quercetin in human erythroleukaemia cells. Biochem J 1994; 300: 201–209.
23.
Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA: The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate 2008; 68: 1773–1789.
24.
Karin M, Clevers H: Reparative inflammation takes charge of tissue regeneration. Nature 2016; 529: 307–315.
25.
Gurtner GC, Werner S, Barrandon Y, Longaker MT: Wound repair and regeneration. Nature 2008; 453: 314–321.
26.
Martin P, D’Souza D, Martin J, Grose R, Cooper L, Maki R, McKercher SR: Wound healing in the PU.1 null mouse – tissue repair is not dependent on inflammatory cells. Curr Biol 2003; 13: 1122–1128.
27.
Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP: Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56–65.
28.
Martin P, Leibovich SJ: Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005; 15: 599–607.
29.
Hübner G, Brauchle M, Smola H, Madlener M, Fässler R, Werner S: Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 1996; 8: 548–556.
30.
Lanning DA, Diegelmann RF, Yager DR, Wallace ML, Bagwell CE, Haynes JH: Myofibroblast induction with transforming growth factor-β1 and -β3 in cutaneous fetal excisional wounds. J Pediatr Surg 2000; 35: 183–187.
31.
Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G: The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807–1816.
32.
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349–363.
33.
Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500–503.
34.
Desmouliere A, Chaponnier C, Gabbiani G: Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005; 13: 7–12.
35.
Sun X, Phan TN, Jung SH, Kim SY, Cho JU, Lee H, Woo SH, Park TK, Yang BS: LCB 03–0110, a novel pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor, suppresses scar formation by inhibiting fibroblast and macrophage activation. J Pharmacol Exp Ther 2012; 340: 510–519.
36.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131–138.
37.
Yang K, Kim JH, Kim HJ, Park IS, Kim IY, Yang BS: Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. J Biol Chem 2005; 280: 39058–39066.
38.
Xagorari A, Roussos C, Papapetropoulos A: Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br J Pharmacol 2002 ; 136: 1058–1064.
39.
Yang WS, Kim D, Yi YS, Kim JH, Jeong HY, Hwang K, Kim JH, Park J, Cho JY: AKT-targeted anti-inflammatory activity of the methanol extract of Chrysanthemum indicum var. albescens. J Ethnopharmacol 2017; 201: 82–90.
40.
Suen PW, Ilic D, Caveggion E, Berton G, Damsky CH, Lowell CA: Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 1999; 112: 4067–4078.
41.
Ferri N, Carragher NO, Raines EW: Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol 2004; 164: 1575–1585.
42.
Wang J, Lü H, Liu X, Deng Y, Sun T, Li F, Ji S, Nie X, Yao L: Functional analysis of discoidin domain receptor 2 in synovial fibroblasts in rheumatoid arthritis. J Autoimmun 2002; 19: 161–168.
43.
Avivi-Green C, Singal M, Vogel WF: Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2006; 174: 420–427.
44.
Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, Klein R, Lovett DH, Lin HC, Friedman SL: Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002; 277: 3606–3613.
45.
Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, Lin HC, Friedman SL: DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 2001; 108: 1369–1378.
46.
Xu L, Peng H, Wu D, Hu K, Goldring MB, Olsen BR, Li Y: Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem 2005; 280: 548–555.
47.
Vogel W, Gish GD, Alves F, Pawson T: The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997; 1: 13–23.
48.
Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Goldfarb MP, Glass DJ, Lemke G, Yancopoulos GD: An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1997; 1: 25–34.
49.
Boots AW, Haenen GR, Bast A: Health -effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008; 585: 325–337.
50.
Xie C, Xie Z, Xu X, Yang D: Persimmon (Diospyros kaki L.) leaves: a review on traditional uses, phytochemistry and pharmacological properties. J Ethnopharmacol 2015; 163: 229–240.
51.
Mu MM, Chakravortty D, Sugiyama T, Koide N, Takahashi K, Mori I, Yoshida T, Yokochi T: The inhibitory action of quercetin on lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells. J Endotoxin Res 2001; 7: 431–438.
52.
Manjeet KR, Ghosh B: Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. Int J Immunopharmacol 1999; 21: 435–443.
53.
Rao YK, Fang SH, Tzeng YM: Inhibitory effects of the flavonoids isolated from Waltheria indica on the production of NO, TNF-alpha and IL-12 in activated macrophages. Biol Pharm Bull 2005; 28: 912–915.
54.
Hinz B: Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526–537.
55.
Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548–5557.
56.
Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420: 885–891.
57.
Berton G, Fumagalli L, Laudanna C, Sorio C: Beta 2 Integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils. J Cell Biol 1994; 126: 1111–1121.
58.
Yan SR, Fumagalli L, Berton G: Activation of p58c-fgr and p53/56lyn in adherent human neutrophils: evidence for a role of divalent cations in regulating neutrophil adhesion and protein tyrosine kinase activities. J Inflamm 1995; 45: 297–311.
59.
Mócsai A, Ligeti E, Lowell CA, Berton G: Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 1999; 162: 1120–1126.
60.
Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL: Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000; 21: 148–154.
61.
Bradshaw JM: The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 2010; 22: 1175–1184.
62.
Walsh LA, Nawshad A, Medici D: Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition. Matrix Biol 2011; 30: 243–247.
63.
Calalb MB, Zhang X, Polte TR, Hanks SK: Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun 1996; 228: 662–668.
64.
Calalb MB, Polte TR, Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954–963.
65.
Cary LA, Chang JF, Guan JL: Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 1996; 109: 1787–1794.
66.
Vuori K, Hirai H, Aizawa S, Ruoslahti E: Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. Mol Cell Biol 1996; 16: 2606–2613.
67.
Avizienyte E, Frame MC: Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17: 542–547.
68.
Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ, Labrador P, Klein R, Lovett D, Yancopoulos GD, Friedman SL, Lin HC: Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002; 277: 19206–19212.
69.
Chaudhari R, Tan Z, Huang B, Zhang S: Computational polypharmacology: a new paradigm for drug discovery. Expert Opin Drug Discov 2017; 12: 279–291.
70.
Mencher SK, Wang LG: Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmcol 2005; 5: 3.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.